Download PDF
Geburtshilfe Frauenheilkd 2013; 73(4): R27-R46
DOI: 10.1055/s-0032-1328498
GebFra-Weiterbildung | Refresher
Georg Thieme Verlag KG Stuttgart · New York

Aufgaben der Pathologie in der Begutachtung von Präparaten aus der Frauenheilkunde

J. D. Strehl
,
D. L. Wachter
,
A. Hartmann
Further Information

Publication History

Publication Date:
13 May 2013 (online)

Also available at
    Permissions and Reprints

Einführung

Die Aufgaben der Pathologie in der Begutachtung von Präparaten aus der Frauenheilkunde unterliegen unter Berücksichtigung aktueller Erkenntnisse aus der Forschung einem ständigen Wandel. Zu den klassischen Verfahren zählen die intraoperative Diagnostik, die Zyto- und Histomorphologie; demgegenüber stehen moderne Untersuchungen wie die Immunhistologie und molekularpathologische Analysen. Diese modernen Verfahren bedürfen einer strengen Indikationsstellung und sind ohne Kenntnisse der morphologischen Befunde in der Mehrzahl der Fälle alleine nicht zielführend. Ziel dieses Weiterbildungsartikels soll sein, sowohl die klassischen als auch die modernen Verfahren an ausgewählten Beispielen aus dem Bereich der Pathologie der Mamma und des Genitaltrakts zusammenzufassen.

 

  • Literatur

  • 1 Laucirica R. Intraoperative assessment of the breast: guidelines and potential pitfalls. Arch Pathol Lab Med 2005; 129: 1565-1574
    PubMedGoogle Scholar
  • 2 Leitlinienprogramm Onkologie, DKG, Deutsche Krebshilfe, AWMF. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. 2012. Im Internet: www.awmf.org
    PubMedGoogle Scholar
  • 3 Cserni G, Amendoeira I, Apostolikas N et al. Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines. Eur J Cancer 2003; 39: 1654-1667
    CrossrefPubMedGoogle Scholar
  • 4 Kuehn T, Bembenek A, Decker T et al. A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance. Cancer 2005; 103: 451-461
    CrossrefPubMedGoogle Scholar
  • 5 Strehl JD, Wachter DL, Fasching PA et al. Invasive breast cancer: recognition of molecular subtypes. Breast Care (Basel) 2011; 6: 258-264
    PubMedGoogle Scholar
  • 6 Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752
    CrossrefPubMedGoogle Scholar
  • 7 Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-10874
    CrossrefPubMedGoogle Scholar
  • 8 Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-5685
    CrossrefPubMedGoogle Scholar
  • 9 Fasching PA, Heusinger K, Haeberle L et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 2011; 11: 486
    CrossrefPubMedGoogle Scholar
  • 10 Cheang MC, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-750
    CrossrefPubMedGoogle Scholar
  • 11 Balbi G, Napolitano A, Giordano F et al. Role of the association of high-risk HPV identified by real-time PCR in cervical preneoplastic lesions. Eur J Gynaecol Oncol 2012; 33: 467-471
    PubMedGoogle Scholar
  • 12 Tsoumpou I, Arbyn M, Kyrgiou M et al. p 16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 2009; 35: 210-220
    CrossrefPubMedGoogle Scholar
  • 13 Negri G, Bellisano G, Carico E et al. Usefulness of p 16ink4a, ProEX C, and Ki-67 for the diagnosis of glandular dysplasia and adenocarcinoma of the cervix uteri. Int J Gynecol Pathol 2011; 30: 407-413
    CrossrefPubMedGoogle Scholar
  • 14 Strehl JD, Mehlhorn G, Koch MC et al. HIV-associated hypertrophic herpes simplex genitalis with concomitant early invasive squamous cell carcinoma mimicking advanced genital cancer: case report and literature review. Int J Gynecol Pathol 2012; 31: 286-293
    CrossrefPubMedGoogle Scholar
  • 15 Yemelyanova A, Vang R, Kshirsagar M et al. Immunohistochemical staining patterns of p 53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol 2011; 24: 1248-1253
    CrossrefPubMedGoogle Scholar
  • 16 Shih IM, Kurman RJ. The pathology of intermediate trophoblastic tumors and tumor-like lesions. Int J Gynecol Pathol 2001; 20: 31-47
    CrossrefPubMedGoogle Scholar
  • 17 Wachter DL, Thiel F, Agaimy A. Subinvolution of the placental site 6 years after last delivery. Int J Gynecol Pathol 2011; 30: 581-582
    CrossrefPubMedGoogle Scholar
  • 18 Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164: 1511-1518
    CrossrefPubMedGoogle Scholar
  • 19 Vang R, Shih Ie M, Kurman RJ. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology 2013; 62: 44-58
    CrossrefPubMedGoogle Scholar
  • 20 Wachter DL, Thiel F, Agaimy A. Foreign body reaction after laparoscopic oxiplex administration mimicking peritoneal adenomucinosis: a potential pitfall in frozen section. Int J Gynecol Pathol 2012; 31: 542-544
    CrossrefPubMedGoogle Scholar
  • 21 Munksgaard PS, Blaakaer J. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecologic Oncology 2012; 124: 164-169
    CrossrefPubMedGoogle Scholar